Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antithrombin III: summary of first database update

D A Lane1, R J Olds, S L Thein

  • 1Charing Cross and Westminster Medical School, Hammersmith, London, UK.

Nucleic Acids Research
|September 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stop and Go: Barriers and Facilitators to Care Home Research.

The Journal of frailty & aging·2023
Same author

The haematology of Jamaicans: red cell indices in HbAA, HbAS, HbAC, and HbA-HPFH genotypes.

Journal of community genetics·2022
Same author

Enhanced activity of an ADAMTS-13 variant (R568K/F592Y/R660K/Y661F/Y665F) against platelet agglutination in vitro and in a murine model of acute ischemic stroke.

Journal of thrombosis and haemostasis : JTH·2018
Same author

ADAMTS-13 and von Willebrand factor: a dynamic duo.

Journal of thrombosis and haemostasis : JTH·2017
Same author

Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial.

Journal of internal medicine·2017
Same author

Next-generation sequencing as a tool for breakpoint analysis in rearrangements of the globin gene clusters.

International journal of laboratory hematology·2017
Same journal

Neurochondrin promotes U5 snRNP maturation by regulating AAR2 release from PRPF8.

Nucleic acids research·2026
Same journal

Elongationless start-stop elements are stress-resilient translation gates that are more repressive than uTranslons.

Nucleic acids research·2026
Same journal

Evolution of the ribosomal exit tunnel through the eyes of the nascent chain.

Nucleic acids research·2026
Same journal

Enhancing the performance and interpretability of epigenetic clocks.

Nucleic acids research·2026
Same journal

FABIAN-variant 2026: improved prediction of the effects of DNA variants on transcription factor binding.

Nucleic acids research·2026
Same journal

Structural and biochemical characterization of Grimontia hollisae thermostable direct hemolysin with DNA reveals first Vibrio hemolysin with nuclease activity.

Nucleic acids research·2026
See all related articles

Antithrombin III deficiency, a risk factor for venous thromboembolism, involves genetic mutations. This study analyzes 184 mutations, detailing types I and II deficiencies and their molecular causes.

Area of Science:

  • Genetics
  • Hematology
  • Molecular Biology

Background:

  • Antithrombin III is a key inhibitor of coagulation factors like thrombin and factor Xa.
  • Inherited antithrombin III deficiency increases the risk of early venous thromboembolism.
  • The antithrombin III gene is located on chromosome 1q 23-25.

Purpose of the Study:

  • To compile and analyze mutations in the antithrombin III gene.
  • To categorize deficiencies into Type I (classical) and Type II (variant).
  • To investigate the nature of genetic defects and the role of CpG dinucleotides.

Main Methods:

  • Database compilation of antithrombin III gene mutations.
  • Classification of mutations by deficiency subtype and nucleotide sequence.

Related Experiment Videos

  • Analysis of molecular events and genetic defect types.

    • Main Results:

    • A database containing 184 entries for antithrombin III gene mutations was updated.
    • 68 reports of Type I (classical) deficiencies and 116 reports of Type II (variant) deficiencies were identified.
    • Analysis focused on unique molecular events, genetic defect nature, and CpG dinucleotide roles.

    Conclusions:

    • The study provides a comprehensive overview of antithrombin III gene mutations.
    • Understanding these mutations aids in characterizing venous thromboembolism risk.
    • Further research into genetic defects and CpG dinucleotides can inform deficiency understanding.